Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0OGZEE
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
Mirzotamab clezutoclax
|
|||||
| Synonyms |
ABBV-155
Click to Show/Hide
|
|||||
| Organization |
AbbVie, Inc.
|
|||||
| Drug Status |
Phase 1
|
|||||
| Indication |
In total 2 Indication(s)
Hematologic cancer [ICD11:2B3Z]
Phase 1
Solid tumors [ICD11:2A00-2A0Z|2B50-2F9Z]
Phase 1
|
|||||
| Drug-to-Antibody Ratio |
2
|
|||||
| Antibody Name |
Mirzotamab
|
Antibody Info | ||||
| Antigen Name |
CD276 antigen (CD276)
|
Antigen Info | ||||
| Payload Name |
Undisclosed
|
|||||
| Linker Name |
Undisclosed
|
|||||
| Puchem SID | ||||||
| ChEBI ID | ||||||
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.